Neuroinflammation 10, 142
Naito Y, Fujii A, Sawada H, Oboshi M, Iwasaku T, Okuhara Y, Morisawa D, Eguchi A, Hirotani S, Masuyama T
Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly GLP1 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Is there an upper limit for B12
However, overall body weight was still reduced by 5.0% to 9.8% at the end of week 32 in the groups administered cagrilintide and by 7.2% at the end of week 32 in the group administered liraglutide [1]